ABSTRACT
T
he apolipoprotein E gene (APOE) has 3 different alleles, APOE*E2, APOE*E3, and APOE*E4. The presence of APOE*E4 is the strongest currently known genetic risk factor for Alzheimer disease (AD).
1,2 APOE*E3 is the most common variant in the general population, while the APOE*E2 variant is associated with a lower risk of AD. The APOE variant modifies not only the risk of AD but also the age of onset of cognitive symptoms. 3, 4 Cross-sectional structural MR imaging studies indicated reduced gray matter in elderly APOE*E4 carriers including healthy controls, subjective memory impairment, mild cognitive impairment (MCI), and AD. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] In MCI and AD, the APOE*E4-related GM decrease seems to affect areas involved in AD pathology, notably the hippocampus, amygdala, and mesial temporal cortex [14] [15] [16] [17] but also the left occipital, frontal, and anterior cingulate cortices. 14, 18 In healthy elderly controls, the APOE*E4 effect on brain structure is less clear. Decreased GM volume in the caudate nuclei 14 and the right cingulate gyrus and decreased white matter integrity in right parahippocampal gyrus 19 were found. However, negative data were also reported. 15, 18, 20 In younger APOE*E4 carriers, the results are also more ambiguous. Some studies demonstrated reduced GM in middle-aged 21 and young APOE*E4 carriers 22, 23 compared with the other APOE allele carriers, whereas others reported no APOE*E4 effect throughout adulthood. 20 Longitudinal studies also indicated that among MCI converters, those with a positive APOE*E4 status displayed increased GM atrophy in AD-related brain regions. 24, 25 The current investigation goes 1 step earlier in the degenerative process and assesses the effect of APOE allele status in healthy controls who subsequently developed subtle cognitive decline. To this end, we performed MR imaging and cognitive assessment at baseline in 382 community-dwelling elderly controls. Extensive cognitive assessment was repeated at 18-month follow-up to define a subsample of 181 individuals with a stable condition and 201 with a deteriorating condition. We demonstrated a gradually progressive GM loss in the posterior cingulate cortex as a function of APOE alleles (E2 Ͻ E3 Ͻ E4) only in deteriorating groups, with preserved GM densities in cognitively stable groups.
MATERIALS AND METHODS

Study Protocol and Participants
All data used in the preparation of this article were obtained from a large, population-based study of community-dwelling older adults who have undergone an 18-month follow-up. These community-dwelling subjects were recruited via advertisements in local newspapers and media. All participants had normal or corrected-to-normal visual acuity, and none reported a history of neurologic or psychiatric disorders or alcohol or drug abuse. To avoid contamination by reversible forms of cognitive decline, subjects with vitamin B12 or folic acid deficiency and those with infectious diseases were excluded. Subjects with regular use of neuroleptics, antidepressants, mood stabilizers, anticonvulsant drugs, or psychostimulants and those with contraindications to MR imaging were excluded. Initially, 433 patients were screened. Thirty-seven refused to continue after the first evaluation (no death or illness, but for personal reasons). Fourteen were not considered due to the above-mentioned exclusion criteria. Five among them had substantial abnormal findings on MR imaging at baseline.
The education level was defined according to the Swiss scholar system, in which level 1 ϭ Ͻ9 years (primary school), level 2 ϭ between 9 and 12 years (high school), and level 3 ϭ Ͼ12 years (university). All participants provided written informed consent after formal approval by the local ethics committee.
Neuropsychological Assessment
At baseline, all individuals were evaluated with an extensive neuropsychological battery, including the Mini-Mental State Examination, 26 the Hospital Anxiety and Depression Scale, 27 and the Lawton 
MR Imaging Acquisition
Imaging data were acquired on a clinical routine whole-body 3T MR scanner (Tim Trio; Siemens, Erlangen, Germany). The structural 3D T1 sequence was performed with the following fundamental parameters: 256 ϫ 256 matrix; 176 sections; 1 ϫ 1 ϫ 1 mm 3 ; TE, 2.3 ms; TR, 2300 ms. Additional sequences (T2WI, susceptibility-weighted imaging, diffusion tensor imaging) were used to exclude incidental brain lesions.
Genetic Testing
Whole-blood samples were collected at baseline for all subjects for APOE genotyping. Standard DNA extraction was performed by using either 9-mL ethylenediaminetetraacetic acid tubes (Sarstedt AG, Nümbrecht, Germany) or the Oragene Saliva DNA Kit (DNA Genotek; Kanata, Ontario, Canada); tubes were stored at Ϫ20°C. APOE genotyping was performed on the LightCycler (Roche Diagnostics, Basel, Switzerland) as described previously.
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Statistical Analysis
The voxel-based morphometry analysis was performed by using the FSL software package (http://www.fmrib.ox.ac.uk/fsl/), according to the standard procedure. Demographic and neuropsychological data were compared among groups by using regression models with group (stable versus deteriorating), APOE genotype (3/2, 3/3, 4/3), and a group ϫ genotype interaction term as predictors. Logistic, ordered logistic, and linear regression models were used for binary, ordinal, and respectively continuous variables. Group effects (stable versus deteriorating) were compared by using the Z-test for plain and ordered logistic regressions and the t test for linear regression.
Logistic regression models were built to assess the relationship between cognitive status (dependent variable) and APOE genotyping, GM densities in the 3 areas of interest (posterior cingulate, hippocampus, mesial temporal lobe), age, sex, and education levels (independent variables). Because GM density values were all ranging between 0.32 and 0.87, we transformed them by using z scores (subtracting the overall mean and dividing by the overall SD) and thus calculated the standardized odds ratio, which represents the decrease in estimated risk for a 1-SD change in GM density.
RESULTS
Demographic and Neuropsychological Data
The final sample included 382 subjects with 3D T1 scans available and APOE genotyping. We grouped these subjects into 3 groups: 43 with APOE*E2 (mean age, 74. sCON and 38 with dCON) genotypes. Demographic data and neuropsychological performances at baseline did not differ between sCON and dCON groups (data not shown). As expected, there were group differences at follow-up, with worse cognitive performances of dCON for the Trail-Making Test B (P ϭ .015), Verbal Fluency (P ϭ .045), and the Wisconsin Card Sorting Test (number of categories) (P ϭ .034). The APOE*E4 allele had a negative impact on verbal fluency performance at follow-up (P ϭ .011) with a significant group ϫ APOE interaction (P ϭ .003 for dCON). There was no other significant association between APOE genotyping and neuropsychological performances at follow-up (Table 1 and Online Table) .
Whole-Brain Voxel-Based Morphometry
In a first step, we performed a voxelwise analysis across the entire brain. The posterior cingulate cortex demonstrated a significant difference between APOE*E3 Ͼ APOE*E4 for the dCON group (Fig 1) .
ROI Analysis: APOE Effect on GM Densities in dCON and sCON
In a second step, we additionally performed an ROI analysis in 7 regions of particular interest in the context of cognitive decline (posterior cingulate cortex, hippocampus, mesial temporal lobe, parietal lobe, amygdala, and caudate nucleus) with the occipital lobe as a control region.
In the posterior cingulate, the GM concentration decreased from E2 to E3 to E4 across all participants. When we separated the patients into stable-versus-deteriorating controls, this decrease in GM concentration was present in only the dCON group (Fig 2A  and Table 2 ). Moreover, we found a significant difference between sCON versus dCON in APOE*E4-positive individuals. Concerning the hippocampus, patients with dCON had lower GM concentrations compared with those with sCON, which was significant only in the APOE*E3 group, presumably due to the large sample size (Fig 2B and Table 3 ). In the amygdala, there was a decrease in GM concentration from APOE*E2 to APOE*E3 to APOE*E4 in all participants, and this effect was present only in the sCON but not in the dCON subgroups (Fig 2C and Table 3 ). In the parietal lobe, the pattern was inverse, with increased GM con- centration in those with dCON, notably in those with APOE*E3 and APOE*E4 (Fig 2D and Table 3 ). No significant differences were found in the mesial temporal lobe, occipital lobe, or caudate nuclei (Fig 2E-G and Table 3 ).
Logistic Regression Models
Higher GM densities in the hippocampus, middle temporal lobe, and amygdala were all associated with a decreased risk for 
DISCUSSION
Several studies demonstrated that the presence of the APOE*E4 allele modulates the expression of brain atrophy in MCI and clinically overt AD, increasing the vulnerability of the areas prone to early neurodegeneration such as the hippocampus, amygdala, and mesial temporal lobe. [15] [16] [17] Although higher cortical amyloid ␤ load and decreased metabolism in the above-mentioned areas were reported in the APOE*E4 allele, crosssectional MR imaging studies failed to identify consistent GM decreases associated with this genotype in elderly controls (for a review see Fouquet et al 44 ). The finding in the current investigation that APOE*E4 was related to GM loss in only the subsequently deteriorating but not in the cognitively stable groups might explain these partially conflicting results of previous studies, which typically do not include detailed neuropsychological assessment and follow-up.
The present data show that the APOE*E4 genotype is not associated 
FIG 2.
ROI analysis of GM density depending on APOE status for the 7 target regions for all elderly controls (left-hand side) and separately for subjects with sCON and dCON (right-hand side). One asterisk indicates P Ͻ .05; 2 asterisks, P Ͻ .01; 3 asterisks, P Ͻ .001; 4 asterisks, P Ͻ .0001.
with an increased risk of dCON status at follow-up. Consistent with previous reports in elderly controls, 15, 18, 20 no APOE genotyping-related effect was identified in the hippocampus and mesial temporal cortex in subjects with both sCON and dCON. In agreement with previous observations in this field, these observations indicate that the APOE*E4 allele detrimental effect in terms of structural changes and clinical progression becomes evident only in elderly individuals with significant cognitive deterioration (MCI) or clinically overt symptoms of dementia (early AD). [14] [15] [16] [17] The posterior cingulate cortex is known to be affected early in the AD process with significant hypometabolism in cognitively healthy individuals and those with MCI (both converters and nonconverters; for review see Teipel and Grothe 45 ). In more advanced stages of the degenerative process, this area exhibits subtle atrophy and hypometabolism in subjects with amnestic amyloid-negative AD. 46 Rare cross-sectional studies addressed the impact of APOE genotyping on the structural and functional integrity of the posterior cingulate cortex. Early contributions from the Cardiovascular Health Study indicated an APOE*E4-independent age-related atrophy in the hippocampus and posterior cingulate cortex in healthy elderly controls. 47 More recently, an altered energy metabolism was reported in this area in young adult APOE*E4 carriers. 48 In the same line, Lu et al 49 reported cortical atrophy in the right cingulate gyrus in cognitively intact APOE*E4 carriers. Our observations parallel these findings, suggesting that the presence of this allele may have a detrimental effect on GM density in this vulnerable area.
The strengths of the present study include its longitudinal design, large number of community-dwelling subjects, and detailed neuropsychological testing at inclusion and follow-up. However, some limitations should also be considered. First, in line with recent core clinical criteria for MCI, 50 the identification of deteriorating controls was based on the objective decline in cognitive functions measured by using serial, comprehensive neuropsychological assessments. However, in the absence of longer follow-up and AD biomarker characterization at baseline (including PET amyloid scans or the CSF /amyloid ␤42 ratio), the cognitive fate of these individuals remains uncertain so that they cannot be a priori considered as subjects with incipient AD. Second, the rarity of APOE*E4 homozygotes pre- cluded a detailed analysis of gene-dose effect on GM densities. Third, handedness was not considered as a covariate in our MR imaging analysis, which included both left-and right-handed controls.
CONCLUSIONS
Our data reveal that the presence of the APOE*E4 allele is associated with decreased GM density in the posterior cingulate cortex in dCON, a community-based group of elderly controls who subsequently had subtle cognitive decline at 18-month follow-up. This APOE effect was not identified in cognitively stable controls. Most important, the APOE*E4 allele has no impact on GM density in areas affected early by neurofibrillary tangle formation such as the hippocampus and mesial temporal lobe. These observations suggest that decreased GM density in the posterior cingulate cortex should be systematically detected among APOE*E4 controls because it could represent a structural marker preceding subtle cognitive deficits in the very early stages of the degenerative process. 
